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Abstract
Background: Lung cancer is one of the most prevalent neoplasias in developed countries. Advances in patient survival 
have been limited and the identification of prognostic molecules is needed. Resistance to treatment is strongly related 
to tumor cell adhesion to the extracellular matrix and alterations in the quantity and nature of molecules constituting 
the tumor cell niche. Recently, transforming growth factor beta-induced protein (TGFBI), an extracellular matrix 
adaptor protein, has been reported to be differentially expressed in transformed tissues. Loss of TGFBI expression has 
been described in several cancers including lung carcinoma, and it has been suggested to act as a tumor suppressor 
gene.
Results: To address the importance of TGFBI expression in cancer progression, we determined its expression in NSCLC 
clinical samples using immunohistochemistry. We identified a strong association between elevated TGFBI expression 
and the response to chemotherapy. Furthermore, we transiently over-expressed and silenced TGFBI in human NSCLC 
cell lines. Cells over-expressing TGFBI displayed increased sensitivity to etoposide, paclitaxel, cisplatin and gemcitabine. 
We observed that TGFBI-mediated induction of apoptosis occurred through its binding to αvβ3 integrin. We also 
determined that full-length TGFBI did not induce caspase 3/7 activation but its proteolytic fragments that were < 3 kDa 
in size, were able to activate caspase 3, 7 and 8. This pro-apoptotic effect was blocked by anti-αvβ3 integrin antibodies.
Conclusions: The results shown here indicate that TGFBI is a predictive factor of the response to chemotherapy, and 
suggest the use of TGFBI-derived peptides as possible therapeutic adjuvants for the enhancement of responses to 
chemotherapy.
Background
More than a century ago Paget proponed his "seed and
soil hypothesis" in which the tumor environment (soil)
was just as important as cancer cell itself (seed) [1,2].
Since then, increasing attention has been devoted to the
behavior of stromal cells and to the tumor microenviron-
ment. In fact, it is now well established that minor altera-
tions in one of the constituents of the tumor niche may
cause dramatic reorganizations of the whole system [3].
Hence, binding of cancer cells to the extracellular matrix
(ECM) influences cell behavior and, ultimately, tumor
progression [4].
A panoply of ECM receptors and binding proteins have
been associated with tumor adhesion and cancer progres-
sion [5,6]. One of these molecules is TGFβ1-induced pro-
tein (TGFBI), which is also known as keratoepithelin or
βIg-h3. This protein was first described in TGFβ1-treated
A549 non-small cell lung cancer (NSCLC) cells and was
soon associated with corneal dystrophies, which are the
only known pathological manifestations of genetic muta-
tions in TGFBI [7,8]. This 68-kDa protein contains four
conserved fasciclin-1 (FAS1) domains and a carboxyl-ter-
minal Arg-Gly-Asp (RGD) integrin-binding sequence.
TGFBI mediates integrin binding to ECM proteins such
as collagen, laminin and fibronectin. TGFBI binding to
integrins has been related to the activation of cell prolif-
eration, adhesion, migration and differentiation [9]. This
protein is upregulated in human tumors of the colon [10],
renal [11,12], pancreas [13] and in neuroblastoma [14],
whereas it is down-regulated in breast cancer [15]. TGFBI
has conflicting roles in cancer progression. Depending on
the tissue, TGFBI functions as a promoter or suppressor
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Page 2 of 12of cancer growth. For example, overexpression of TGFBI
in renal, pancreatic or colon carcinoma cells induces cell
migration and increased metastatic potential [12,13,16].
Conversely, Zhang et al. demonstrated that TGFBI-/-
mice were susceptible to both spontaneous and 7,12-dim-
ethylbenz(α)anthracene-induced skin tumors [17]. In
relation to lung cancer, loss of TGFBI expression has been
described in asbestos and radiation-exposed human
bronchial epithelial cells [18,19] and in human lung can-
cer samples [20,21]. 
In the present work, we described an association
between TGFBI expression and the response to chemo-
therapy in NSCLC. In order to characterize the molecular
mechanisms underlying this association, we examined
the effects of TGFBI over-expression and inhibition in
NSCLC cells on the induction of apoptosis after chemo-
therapy. Additionally, we evaluated the effect of soluble
proteolytic fragments of TGFBI on tumor cell survival.
Results
High TGFBI expression in NSCLC samples correlates with 
response to chemotherapy
Loss of TGFBI expression has been associated with the
tumorigenic phenotype of several carcinomas including
lung cancer [[20], and Additional file 1]. It has also been
correlated with enhanced sensitivity to paclitaxel and
etoposide in ovarian carcinoma [22] and a lung adenocar-
cinoma cell line [20], respectively.
In order to determine if loss of TGFBI expression corre-
lated with the chemotherapeutic response in clinical sam-
ples, we retrospectively analyzed pre-chemotherapy
TGFBI protein expression in a series of 47 stage IV
NSCLC samples by immunohisto-chemistry. TGFBI
expression was significantly (p = 0.003) higher in patients
who responded to chemotherapy (average TGFBI H score
= 170) compared to patients whose cancer progressed
(average score = 110) or who had stable disease (average
score = 120) (Figure 1). We did not observe any correla-
tion between TGFBI expression and other clinico-patho-
logical parameters analyzed such as gender, age or tumor
histology. Detailed information regarding TGFBI expres-
sion in each tumor sample, patient outcome and the type
of chemotherapy administered is provided in Additional
file 2.
We also performed Kaplan-Meier analysis of overall
survival on the same series of patients. Data shown in
Additional file 3 illustrate that patients expressing higher
levels of TGFBI show a trend towards better survival (p =
0.053). This data, in spite of not being significant, sug-
gests its possible use as a candidate prognostic factor.
Nevertheless, analyses performed in greater number of
samples should be made to definitively test this.
TGFBI over-expression contributes to NSCLC responses to 
chemotherapy
To identify the mechanism underlying the role of TGFBI
in tumor cell response to chemotherapy, we transiently
over-expressed TGFBI in the metastatic NSCLC cell line
NCI-H1299, which has a low basal expression of this pro-
tein (H1299-TGFBIve). Additionally, we silenced TGFBI
in non-metastatic NSCLC NCI-A549 cells, which express
high basal levels of this protein (A549-TGFBIsi). Basal
expression and the efficiency of TGFBI over-expression
and silencing are shown in Additional file 4. Using this
experimental approach, we determined the effects of
TGFBI expression on cell viability using the neutral red
assay. TGFBI silencing in A549 cells increased cell viabil-
ity while over-expression in H1299 cells diminished sur-
vival (Figure 2).
Since cells that over-expressed TGFBI showed reduced
viability, we postulated that they may be more sensitive to
chemotherapy than cells not expressing this protein. To
explore this, TGFBI over-expressing (H1299-TGFBIve) or
silenced (A549-TGFBIsi) NSCLC cells were treated with
paclitaxel, etoposide, cisplatin or gemcitabine and mea-
sured their IC50. A549-TGFBIsi cells displayed a higher
IC50 for all drugs assayed compared to treated non-trans-
fected or empty vector-containing cells, with more prom-
inent effects observed in cells treated with paclitaxel and
etoposide (Figure 3A). On the contrary, H1299-TGFBIve
cells displayed a significant decrease in their IC50 (Figure
3B) compared to control cells. We measured PARP cleav-
age in A549-TGFBIsi and H1299-TGFBIve cells by West-
ern blot analysis after their exposure to etoposide. After
etoposide treatment, PARP cleavage in A549-TGFBIsi
Figure 1 High TGFBI expression is associated with a positive re-
sponse to chemotherapy in NSCLC samples. Mean H-score expres-
sion levels of TGFBI were determined by immunohistochemistry (n = 
47) in a series of NSCLC biopsies obtained before chemotherapy. Sta-
tistical differences between response and stabilization and response 
versus progression were analyzed using Kruskal-Wallis and pair-wise 
Mann-Whitney U tests. *p < 0.05; **p < 0.01.
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Page 3 of 12cells was reduced (Figure 3C), whereas H1299-TGFBIve
displayed higher PARP activation (Figure 3D). Therefore,
we confirmed that TGFBI expression augmented cell
death in NSCLC cells after exposure to chemotherapeutic
drugs. Interestingly, the increase observed in cell death
following chemotherapy occurred independently of the
drug used and, therefore, of the cellular process targeted
by these compounds (cytoskeleton remodeling and cell
proliferation), which suggests that elevated expression of
TGFBI has a direct pro-apoptotic effect on NSCLC cells.
To test these, we measured cell viability in non treated
NSCLC cells in which TGFBI had been silenced (A549
NSCLC cells) or over-expressed (H1299 NSCLC cells).
The results obtained confirmed our hypothesis: those
cells that had TGFBI silenced were more viable, while on
the contrary, if this protein was over-expressed they pre-
sented reduced cell viability (Additional file 5).
NSCLC cells exposed to recombinant soluble TGFBI 
displayed an increased susceptibility to chemotherapy
Given that TGFBI is an extracellular protein, we next
sought to ascertain if the observed effects were reproduc-
ible by the addition of exogenous recombinant TGFBI
(rh-TGFBI). We measured caspase 3/7 activity in A549
and H1299 NSCLC cells after being exposed to increasing
amounts of rh-TGFBI. As shown in Figure 4A, no pro-
apoptotic effect was observed in response to low concen-
trations of recombinant TGFBI but, following exposure
to 20 μg/mL rh-TGFBI, a 1.4- and 1.7-fold increase in cas-
pase 3/7 activity was seen in A549 and H1299 cells,
respectively. We also observed the same results when the
equivalent amounts of recombinant protein were used to
coat 96-well plates before seeding the carcinoma cells
onto them (Figure 4B).
To determine if NSCLC binding to soluble recombinant
TGFBI also contributed to improved responses to che-
motherapy, we analyzed caspase 3/7 activation in NSCLC
cells exposed to 20 μg/mL rh-TGFBI and treated with
etoposide at a concentration of 5 μM and 50 μM for A549
cells and H1299 cells, respectively. NSCLC cells treated
with etoposide in the presence of recombinant TGFBI
displayed higher caspase 3/7 activity compared to cells
treated with the chemotherapeutic drug alone (Figure
4C). As expected, when seeding A549 and H1299 cells
onto TGFBI coated 96-well plates, an increased response
to etoposide was also induced (Figure 4D).
TGFBI-induced cell death is mediated through interaction 
with the αvβ3 integrin
Once we demonstrated that TGFBI induced apoptosis in
our system, we next wanted to ascertain which cell sur-
face receptor was required. Integrins are the only type of
cellular receptors that have been shown to mediate
TGFBI signaling. To determine which integrin was
involved in TGFBI binding to NSCLC cells, we per-
formed cell adhesion assays using NSCLC cells cultured
onto plate-bound rh-TGFBI (1 μg/mL) in the presence of
a variety of anti-integrin blocking antibodies. The adhe-
sion of A549 and H1299 cells to rh-TGFBI was blocked
only in the presence of the anti-αvβ3 integrin monoclonal
antibody (Figures. 5A and 5B). A noticeable difference in
basal cell adhesion to rh-TGFBI was observed between
Figure 2 Changes in TGFBI expression affects cell viability. Cell viability of transfected NSCLC cells was determined by neutral red staining 24, 48 
and 72 h after transfection with a TGFBI siRNA plasmid or a TGFBI expression vector. Transfection with empty vector was used as a negative control 
for all experiments. Three independent experiments were performed. Statistical comparisons of the differences between control and transfected cells 
were performed using Student t-test (* p < 0.05; **p < 0.01).
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Figure 3 TGFBI sensitizes NSCLC cells to chemotherapy. A549 cells transfected with TGFBI siRNA plasmid (TGFBIsi) (A), and H1299 cells transfected 
with TGFBI expression vector (TGFBIve) (B), were exposed to increasing amounts of different cytotoxic agents for 48 h and cell viability was measured. 
Three independent experiments were performed. Comparisons to analyze statistical differences between control and transfected cells were per-
formed using Student t-test (* p < 0.05; ** p < 0.01). IC50 for each experimental condition is indicated. (C, D) PARP-1 cleavage was detected by Western 
blot analysis of total protein extracts derived from A549-TGFBIsi (C) and H1299-TGFBIve (D) transfected cells treated with etoposide for 48 h. One rep-
resentative experiment out of three is shown.
Concentration (µM)
Cisplatin
0
50
100
0 10 20 30 40%
 c
el
l d
ea
th
**
**
*
**
Irigoyen et al Figure 3 BA A549 H1299
Cisplatin
0
50
100
0 20 40 60 80 100%
 c
el
l d
ea
th
**
**
** **
Concentration (µM)
Taxol
0
50
100
0 0,01 0,1 1 10 100%
 c
el
l d
ea
th
Concentration (µM)
*
loglog
Taxol
0
50
100
0 0,01 0,1 1 10%
 c
el
l d
ea
th
** **
*
Concentration (µM)
Gemcitabine
0
50
100
0 40 80 120%
 c
el
l d
ea
th
160
** **
** ** **
Concentration (µM)
cont A549 TGFBI si empty vectorH1299 TGFBI ve
**
Etoposide
0
50
100
0
20 40 60 80 100120%
 c
el
l d
ea
th
Concentration (µM)
**
**
*
**
Etoposide
0
50
100
0 10 20 30 40%
 c
el
l d
ea
th
Concentration (µM)
** **
**
β-actin
PARP-1
C
β-actin
PARP-1
D
co
nt
ro
l
TG
FB
Is
i
et
op
os
TG
FB
Is
i 
et
op
os
A549
co
nt
ro
l
TG
FB
Iv
e
et
op
os
TG
FB
Iv
e 
et
op
os
H1299
**
Gemcitabine
0
50
100
0 40 80 120 160%
 c
el
l d
ea
th
Concentration (µM)
** ** ** **
Irigoyen et al. Molecular Cancer 2010, 9:130
http://www.molecular-cancer.com/content/9/1/130
Page 5 of 12A549 and H1299 cells, the former showing lower adhe-
sion than the latter. When we determined by flow cytom-
etry the expression levels of the integrin αvβ3 on the
surface of both cell lines, we observed that A549 cells
expressed lower αvβ3 integrin than H1299 cells. This is
probably the cause of their lower adhesion to TGFBI
coated plates (Figure 5C).
It has been previously shown that αvβ3 integrin medi-
ates paclitaxel sensitivity of ovarian cancer cells that tran-
siently expressed TGFBI [22]. Therefore, to determine if
this integrin influences TGFBI-mediated NSCLC cell sus-
ceptibility to chemotherapy, we incubated NSCLC cells
with a blocking antibody specific for αvβ3, 1 h before the
addition of rh-TGFBI (20 μg/mL) for 24 h and an further
exposure to etoposide (5 μM for A549 cells and 50 μM for
H1299 cells) for additional 24 h. As shown in figure 5D,
blocking αvβ3 integrin resulted in impaired TGFBI-
induced caspase 3/7 activity in both the presence and
absence of etoposide. All these results demonstrated that
this integrin participates in TGFBI-mediated induction of
NSCLC cell apoptosis.
RGD peptides derived from TGFBI influence the 
susceptibility of NSCLC cells to chemotherapy through 
caspase 8 and caspase 3/7 activation
TGFBI contains a carboxy-terminal Arg-Gly-Asp (RGD)
integrin binding sequence. Given that integrin-mediated
binding of a cell to the ECM or to small soluble peptides
can have contrasting effects on survival, with the latter
resulting in survival and the former leading to cell death
[23], we addressed whether TGFBI-derived RGD-con-
taining peptides played a role in TGFBI-mediated apop-
tosis.
The supernatants from the culture of A549 and H1299
NSCLC cells transiently transfected with the TGFBI
expression vector were collected 24 h after transfection,
and filtered through a membrane with 3 kDa molecular
weight cut-off. Two different cell supernatants were
obtained (TGFBI < 3 kDa and TGFBI > 3 kDa). They were
Figure 4 High concentration of rh-TGFBI protein increases cell death and potentiates NSCLC responses to chemotherapy. Caspase 3/7 ac-
tivity was measured in A549 (white histograms) and H1299 (black histograms) NSCLC cells seeded onto non coated 96-well plates and further treated 
with increasing amounts of rh-TGFBI (A), or seeded onto 96 well plates coated with increasing amounts of rh-TGFBI (B), using the caspase 3/7 Glo-
assay from Promega. (C and D) Caspase 3/7 activity of 24 h etoposide-treated A549 (5 μM) and H1299 (50 μM) cells seeded onto non coated 96-well 
plates and further exposed for 24 h to increasing amounts of rh-TGFBI previous to etoposide exposure (C) or seeded onto 96-well plates coated with 
increasing amounts of rh-TGFBI before exposure to etoposide (D). Statistical analyses were performed using Student t-test to compare caspase 3/7 
activity in treated cells to non-treated cells (* p < 0.05; **p < .01).
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Page 6 of 12separately added to A549 and H1299 cell cultures and, 24
h later, caspase 3/7 cleavage was evaluated to determine if
TGFBI-derived peptides influenced cell apoptosis.
NSCLC cells over-expressing TGFBI generated a TGFBI-
specific band, which was smaller than the full-length 68
kDa recombinant protein, indicating that the TGFBI pro-
tein was digested (Figure 6A). The results presented in
figure 6B demonstrated that only the smaller TGFBI-
derived fragments (TGFBI < 3 kDa) induced caspase 3/7
activity in both A549 and H1299 NSCLC cells, while
supernatants containing proteins larger than 3 kDa in
size, or those obtained from non-transfected cells, had no
effect on caspase activity. Even more, cell supernatants
containing proteins larger than 3 kDa were unable to
enhance the etoposide-induced increase in caspase 3/7
activation, whereas those supernatants containing
smaller TGFBI fragments increased caspase activation
similar to that induced by treatment of NSCLC cells with
recombinant TGFBI protein. To support these observa-
tions, we exposed H1299 cells to short synthetic peptides
derived from the RGD region of the TGFBI protein
described by Kim and co-workers [24]. Results shown in
Additional file 6 demonstrated that peptides containing
the full RGD sequence induced cell death while a RGE
mutant did not induce it.
Additionally, we found that the pro-apoptotic effects of
the TGFBI < 3 kDa supernatants were abrogated by pre-
incubating the NSCLC cells with an anti-αvβ3 integrin
blocking antibody. We further confirmed the role of the
αvβ3 integrin in TGFBI induced cell death by transfection
of H1299 with an anti-β3 integrin sh-RNA plasmid and
further exposing these cells to 3 < kDa supernatants
derived from TGFBI over-expressing cells for 48 h. Cas-
pase 3/7 activity remained basal in β3 integrin silenced
cells whereas it was induced in H1299 cells transfected
with a scramble-shRNA (Additional file 7).
Figure 5 TGFBI influences NSCLC susceptibility to chemotherapy through binding to the αvβ3 integrin. Adhesion of calcein-labeled A549 (A) 
and H1299 (B) NSCLC cells to rh-TGFBI coated (1 μg/mL) 96-well plates was evaluated in the presence of antibodies against several integrins. Statistical 
analyses were performed using Student t-test and comparing treated cells to control cells (**p < 0.01). (C) Flow cytometry analysis of basal αvβ3 inte-
grin expression in A549 cells (dashed histogram), H1299 cells (line histrogram) or isotype control (dotted histogram). (D) Caspase 3/7 detection in A549 
and H1299 cells seeded onto non-coated 96 well-plates, pre-incubated for 1 h with anti-αvβ3 monoclonal blocking antibody, exposed to rh-TGFBI (20 
μg/mL) for 24 h and further treated with etoposide at the IC50 (5 μM for A549 cells and 50 μM for H1299 cells) for additional 24 h. Statistical comparisons 
were performed using Student t-test. **p < 0.01 for the comparison of the activity control cells versus integrin blocked cells. ##p < 0.01 for the com-
parison of the activity of etoposide-treated cells versus cells treated in the presence of the anti-integrin blocking antibody.
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recruited to a complex containing unligated αvβ3 integ-
rins, where it is activated and mediates apoptosis [25]. In
order to determine whether this caspase pathway is acti-
vated by TGFBI fragments, we measured caspase 8 acti-
vation in NSCLC cells exposed to supernatants
containing TGFBI fragments < 3 kDa. Caspase-3/7 acti-
vation peaked 24 h after exposure to cell supernatants,
while caspase-8 activation peaked 12 h earlier, which was
expected due to its known previous activation in the cas-
pase activation cascade (Figure 6C and 6D).
All of these results demonstrated that proteolytic frag-
ments derived from TGFBI induced cell death through
binding to the αvβ3 integrin on the surface of NSCLC
cells and the subsequent activation of caspases 8 and cas-
pase 3/7 signaling. These findings may explain the impor-
Figure 6 Peptides derived from TGFBI mediate NSCLC cells response to chemotherapy and the induction of caspase 8 and caspase 3/7 ac-
tivation. (A) Western blot detection of proteolytic fragments of TGFBI in H1299 and A549 cells transiently transfected with the TGFBI expression vector. 
(B) Detection of caspase 3/7 activity in A549 and H1299 cells exposed for 24 h to cell supernatants derived from cultures of A549 and H1299 cells tran-
siently transfected with the TGFBI expression vector. Control: non-treated cells; Control > 3 kDa: NSCLC cells exposed to supernatants from non-
transfected cell cultures containing fragments larger than 3 kDa in size; Control < 3 kDa: NSCLC cells exposed to supernatants from non-transfected 
cell cultures containing fragments smaller than 3 kDa in size; TGFBI > 3 kDa: NSCLC cells exposed to supernatants from TGFBI-transfected cells con-
taining fragments larger than 3 kDa in size; TGFBI < 3 kDa: NSCLC cells exposed to supernatants from TGFBI-transfected cells containing fragments 
smaller than 3 kDa in size; αvβ3: cells blocked with anti-αvβ3 blocking antibody 1 h before the addition of the supernatant; Et: Cells exposed to IC50 
etoposide for 24 h. Statistical analyses were performed using Student t-test to compare caspase 3/7 activity in control cells (** p < 0.01) or etoposide 
treated cells (## p < 0.01) to the caspase activity in cell cultures treated with supernatants. (C) Caspase 8 and (D) caspase 3/7 detection in A549 and 
H1299 cells maintained for different time-periods in the presence of TGFBI < 3 kDa supernatant. Statistical analyses were performed using Student t-
test and the caspase activity of treated cells was compared to that of untreated cells. (*p < 0.05; **p < 0.01).
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expression and the response to chemotherapy found in
NSCLC clinical biopsies.
Discussion
Non-small cell lung cancer constitutes the largest sub-
group of lung cancers, accounting for approximately 80%
of the diagnosed cases of lung cancer. Most patients with
NSCLC are diagnosed with locally advanced or meta-
static disease and have very low survival expectancy
[26,27]. The existing treatment options for these patients
have considerable limitations in effectiveness and safety.
Current efforts have focused on discovering markers that
are predictive of the outcome of treatment, facilitating a
more specific approach to therapy.
In this report, we have demonstrated a significant asso-
ciation between TGFBI expression and the success of
chemotherapy. We evaluated 47 NSCLC clinical samples
and we detected low levels of TGFBI in those patients
who did not respond to chemotherapy. In contrast, in
patients who did respond to chemotherapy, we found
higher levels of this protein in their tissue samples, sug-
gesting a possible role of this molecule as a surrogate
marker for response to therapy.
TGFBI was described as a soluble TGFβ1-induced
ECM binding protein; it mediates cell adhesion to extra-
cellular proteins such as collagen, fibronectin and lamin-
ins through integrin binding [9]. Cell adhesion to ECM
has been consistently reported as one of the mechanisms
used by tumor cells to resist chemotherapy [28,29]. In this
process, the ECM proteins play a critical role [30]. Here,
in contrast to what was expected, we demonstrated that
TGFBI silencing increased cell viability and over-expres-
sion had the opposite effect. Additionally, we observed an
increase in chemo-sensitivity to a variety of chemothera-
peutic agents when cells over-expressed TGFBI. This
finding indicates that TGFBI promotes cell death through
a mechanism that is independent of the drug used.
Ahmed et al., suggested that TGFBI-mediated apoptosis
was a direct effect of TGFBI on microtubule stabilization
[22], and in our case we observed a direct caspase activa-
tion after TGFBI exposure regardless of using microtu-
bule targeted therapy or other chemotherapeutic drugs.
In spite of an apparent discrepancy, both mechanisms
could be occurring at one time: full-length TGFBI could
promote microtubule stabilization while its proteolytic
fragments induce cell death.
We also demonstrated that TGFBI binds to NSCLC
cells through the αvβ3 integrin. Considering the variety of
integrin receptors that TGFBI protein can bind to, the
specific identification of αvβ3 integrin as the key receptor
highlights the pleiotropic nature of TGFBI-integrin sig-
naling. In fact, TGFBI-mediated cellular response may
vary widely depending on the integrin this protein binds
to and the tissue location of this interaction. For example,
TGFBI-αvβ5 integrin binding on vascular smooth muscle
cells leads to increased adhesion and migration via Akt,
ERK and FAK phosphorylation [31]; in other cells such as
keratinocytes and corneal epithelial cells, TGFBI-medi-
ated cell adhesion and migration is achieved through its
binding with α3β1 integrin [32,33]. Interestingly, it has
been described that TGFBI promoted anti-angiogenic
responses in HUVEC cells through binding to the αvβ3
integrin [34], which is the same integrin that mediates
TGFBI adhesion to ECM in response to acute hypoxia in
lymphatic endothelial cells [35]. In our experiments, we
observed that TGFBI binds to αvβ3 integrin on NSCLC
cells and blocking this interaction abrogates the pro-
apoptotic effect of TGFBI.
Recent published studies have demonstrated that, while
ligand-bound αvβ3 integrin activates cell survival path-
ways and suppresses pro-apoptotic signals, non-ligated
αvβ3 integrin or integrins bound to soluble substrates
actively promote apoptosis [23]. In our case, TGFBI
mediated the susceptibility of NSCLC cells to chemother-
apy and this may be the result of direct TGFBI induction
of cell death through the binding of its proteolytic frag-
ments (< 3 kDa) to the αvβ3 integrin. A number of previ-
ous studies have reported that high concentrations of
TGFBI promoted the apoptosis of CHO and H1299 cells
[24,36] via RGD peptides, which are the products of
TGFBI proteolysis, similar to what has been described for
other ECM molecules [37]. This aspect may be of clinical
relevance given that soluble ligands for αvβ3 integrin have
been used in pre-clinical animal models of melanoma and
ovarian cancer [38,39]. Additionally, TGFBI-derived pep-
tides could be used in the near future as adjuvants in lung
cancer therapy. Questions such as how TGFBI-derived
peptides will affect non-tumor cells, which protease cata-
lyzes TGFBI proteolysis and in what instances this prote-
olysis is activated all warrant future investigation.
In summary, here we provide evidence of the usefulness
of TGFBI as a predictor of the outcome of chemotherapy
in NSCLC and highlight the role of proteolytic TGFBI
fragments in αvβ3 integrin-dependent NSCLC cell death.
Conclusions
In the current report we have demonstrated an associa-
tion between TGFBI expression and the outcome of che-
motherapy in patients with NSCLC. This protein has
been described to be down regulated in NSCLC cells but,
currently, little is known about its relationship with che-
motherapy outcomes. Despite the remarkable develop-
ment of targeted therapies for advanced NSCLC, little
improvement in overall survival has been achieved.
Therefore, the identification of predictive or surrogate
markers of the response to chemotherapy would permit
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Page 9 of 12selection of patients who are most likely to positively
respond to treatment [40].
We demonstrated that TGFBI-derived proteolytic frag-
ments induced cell death when this protein was present
at high concentrations in NSCLC cells. TGFBI-mediated
cell death depended on the binding of TGFBI proteolytic
fragments to αvβ3 integrin and the induction of caspase 8
and caspase 3/7. This pro-apoptotic effect occurred inde-
pendent of the chemotherapeutic drug used. Therefore,
the current findings offer new perspectives in the use of
TGFBI-derived peptides as co-adjuvants for the develop-
ment of new therapeutics.
Materials and methods
NSCLC patients and response criteria
To analyze NSCLC susceptibility to chemotherapy, a
series of retrospective samples from 47 stage IV NSCLC
patients were obtained prior to chemotherapy at the
Clínica Universidad de Navarra between 2000 and 2006.
Eligible patients needed to be 18 or older at the time of
treatment, with a histological confirmed diagnosis of
stage IV NSCLC, treated in our institution with a plati-
num-taxane combination regimen in a first-line setting
and followed at least until tumor response assessment. In
addition, sufficient tumor sample from original biopsy
was required in order to perform immunohistochemical
analysis. The records of 103 stage-IV NSCLC consecutive
patients treated in our institution were initially selected.
After evaluation, 22 of the 103 patients were excluded
because chemotherapy was not administered in a first-
line setting. Other 19 patients were not eligible due to
unavailability of sufficient tumor sample to perform
immunohistochemical analysis. Finally, 15 patients ini-
tially treated in our institution were lost during follow-up
before tumor response was assessed and thus were also
excluded. Therefore the final number of samples analyzed
was reduced to 47 cases.
Clinico-pathological features of these 47 patients are
shown in Additional file 2. Histological diagnosis was
performed according to the WHO classification [41].
REMARK criteria were followed throughout all the study
[42]. Criteria for response were established as already
published following RECIST criteria [43]. Complete
response was defined as the disappearance of all target
and non-target lesions, and the normalization of tumor
marker level confirmed by repeat assessments that should
be performed no less than 4 weeks after the criteria for
response is first met. During this time no new lesions
should appear. Partial response was defined as a greater
than or equal to 30% decrease in the sum of the largest
one-dimensional measurements, maintained for a mini-
mum of 4 weeks. Stable disease was defined as change in
the sum of the products or diameters, respectively, insuf-
ficient for partial response and progressive disease, main-
tained for a minimum of 4 weeks from baseline [44]. The
study protocol was approved by the ethics committee.
Immunohistochemistry of clinical biopsies from NSCLC 
patients
Formalin-fixed paraffin-embedded tissue sections were
evaluated. Endogenous peroxidase activity was quenched
and antigen retrieval was carried out by pressure cooking.
Non-specific binding was blocked using 5% normal goat
serum in Tris-buffered saline (TBS) for 30 min. Sections
were incubated with anti-TGFBI antibody (1:25; Protein-
tech group, Chicago, USA) overnight at 4°C. Sections
were then incubated with Envision polymer (Dako,
Glostrup, Denmark) for 30 min at room temperature.
Peroxidase activity was developed using diaminobenzi-
dine and counterstained with hematoxylin before mount-
ing in DPX mounting medium (BDH Chemical, Poole,
UK). The specificity of the antibody was assessed by
Western blot analysis of proteins from lung tumor sec-
tions (Additional file 1). Negative controls were carried
out by omission of the primary antibody or incubation
with an isotype control antibody.
Immunostaining evaluation
Two independent, blinded observers (M.J.P and M.I.)
evaluated the intensity and extensiveness of staining in all
of the study samples. The evaluation of TGFBI expression
was performed using the H-score system [45]. Briefly, the
percent of positive cells (0-100%) was scored and the
intensity of staining was assessed in comparison to an
external positive control (1+, mild; 2+, moderate and 3+,
intense labeling). A final H score (0-300) was established
by multiplying the percentage of labeled cells and the
intensity of staining. Disagreements were resolved by
common re-evaluation.
Cell culture
Human NSCLC cell lines derived from adenocarcinoma
(NCI-A549) and large cell carcinoma (NCI-H1299) were
purchased from American Type Culture Collection
(ATCC, LGC-Promochem SL, Barcelona, Spain) and
grown in RPMI 1640 medium (GIBCO, Barcelona, Spain)
supplemented with 10% FBS and penicillin-streptomycin
at 100 U/mL each. Cell cultures were incubated at 37°C in
a humidified 5% CO2 incubator.
TGFBI over-expression and silencing
To over-express TGFBI in H1299 cells (H1299 TGFBIve),
2 × 105 cells/well were transfected with 1 μg of the
pCMV6-XL4 plasmid vector containing TGFBI cDNA
(Origene, MD, USA) using 2 or 3 μl of FuGENE 6 Trans-
fection Reagent (Roche, IN, USA) in 97 μl of Opti-MEM
medium (Invitrogen, Barcelona, Spain) following manu-
facturer's instructions.
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(A549-TGFBIsi) were transfected by electroporation with
10 μg of a commercially available shRNA targeting
TGFBI cloned in a pRS plasmid vector (Origene, MD,
USA). Cell transfections were performed in Opti-MEM
medium (Invitrogen) using a Biorad Gene Pulsar I elec-
troporator (Hercules CA, USA), with the capacitance set
at 100 F and the voltage at 500 V. Transfection efficiency
was confirmed by Western blot of NSCLC supernatants
(Additional file 4).
Determination of cell viability
For cell viability assays, 104 NSCLC cells were plated in
96-well plates (TPP, St. Louis MO, USA) in complete
RPMI medium as described [46]. To measure the role of
TGFBI expression in NSCLC sensitivity to chemotherapy,
A549 TGFBIsi and H1299 TGFBIve cells were seeded in
96-well plates. When cells reached confluence, increasing
amounts of the four different chemotherapeutic drugs
were added to NSCLC cells in complete cell culture
media for 48 h and cell viability was assayed. The IC50 for
etoposide in non-transfected cells was determined exper-
imentally and used to measure caspase 3/7 activity and
PARP cleavage (50 μM for H1299 cells and 5 μM for A549
cells).
To determine the influence of rh-TGFBI protein on cell
viability, soluble recombinant human TGFBI (rh-TGFBI)
purchased from R&D, was added to the cells in increasing
concentrations (0.1, 1, 5, 10 and 20 μg/mL) and cell viabil-
ity was assayed after 24 h.
Cell adhesion assay
To determine which integrin is involved in NSCLC cell
adhesion to TGFBI, 1 × 106 cells/mL were labeled with 10
μM calcein-AM (Fluka, Steinheim, Germany) in adhe-
sion-medium (RPMI 0.5% BSA, 20 mM HEPES). Cells in
suspension were incubated with gentle rocking for an
hour in the presence 1 μg/mL of each monoclonal anti-
integrin blocking antibody. Afterwards, 104 cells were
seeded onto 1 μg/mL rh-TGFBI coated wells, and cell
adhesion was assayed as described [46]. Six replicates
were plated for each condition. The following blocking
monoclonal antibodies were used: anti-α1 integrin
(MAB1973Z, Chemicon International, CA, USA), anti-β3
integrin (MAB2023Z, Chemicon International), anti-α4
integrin (340976, Becton Dickinson, NJ, USA), anti-integ-
rins αv, β1, β2, α5β1, αvβ3, αvβ5 (Integrin Classics Kit,
ECM435, Chemicon Interational) and a nonspecific IgG
(MAB004, R&D Systems).
PARP cleavage detection by Western blot analysis
To determine the effect of TGFBI expression on PARP
cleavage in the NSCLC cells in response to chemother-
apy, 106 NSCLC cells were cultured in RPMI complete
medium on 10 cm2 plates and allowed to adhere for 24 h.
After this time, etoposide was added at the IC50 (50 μM
for H1299 cells and 5 μM for A549 cells) for 48 h. Then,
protein extracts were collected and transferred to nitro-
cellulose membranes as described [46]. The membranes
were blocked by incubating them overnight in a solution
of 5% non-fat dry milk in PBS-Tween. Primary PARP
antibody (Cell Signaling, MA, USA) incubation was per-
formed for 1 h at room temperature (1:1000 dilution).
Membranes were washed three times with PBS-Tween
0.2% and incubated with an HRP-conjugated anti-rabbit
IgG (sc-2030, Santa Cruz Biotechnology, CA, USA) in 5%
non-fat dry milk in PBS-Tween. The signal was developed
using the Lumi-lightPLUS Western Blotting Kit (Roche
Molecular Biochemicals, Mannheim, Germany).
Integrin αvβ3 flow cytometry
For determination of integrin αvβ3 expression on the sur-
face of NSCLC cells, 1 × 105 cells A549 and H1299 cells
were cultured to subconfluency in 6 well plates contain-
ing 1 mL of complete cell growth media. Afterwards, the
cells were harvested and resuspended in 100 μl of staining
buffer (5% FBS, EDTA 2 mM in PBS) and incubated for 10
min at room temperature with a concentration of 1 μg/ml
of the, anti-integrin αvβ3 (Integrin Classics Kit, ECM435,
Chemicon Interational) monoclonal antibody or a non-
specific IgG (MAB004, R&D Systems). Afterwards, the
cells were washed with staining buffer and subsequently
incubated with 1:500 green-fluorescent Alexa Fluor 488
anti-mouse-secondary antibodies (Molecular Probes) at
room temperature for 10 min. Cells were washed twice
with staining buffer and analyzed on a FACScan flow
cytometer using Cellquest software (BD-PharMingen).
Caspase 3/7 and caspase 8 determination
To determine caspase 3/7 activity, 104 cells were cultured
in RPMI complete medium on 96-well plates coated with
increasing amounts of rh-TGFBI (rhTGFBI) and allowed
to adhere for 24 h. After this time caspase 3/7 activity was
measured. In some instances, the cells were allowed to
adhere to non-coated wells for 8 h and then incubated
with increasing amounts of rh-TGFBI for 24 h. To mea-
sure caspase 3/7 activity after etoposide treatment,
NSCLC cells were incubated with this drug at the IC50 (50
μM for H1299 cells and 5 μM for A549 cells) for addi-
tional 24 h after being treated with or seeded onto rh-
TGFBI, and caspase activity was measured afterwards.
For αvβ3 integrin blocking experiments, 104 cells were
cultured in RPMI complete medium on 96-well plates
and always allowed to adhere to non-coated surfaces for 8
h. After this time, the cells were pre-incubated for 1 h
with 1 μg/mL of the monoclonal anti-αvβ3 integrin anti-
body (Chemicon, IL, USA). Then, 20 μg/mL of rh-TGFBI
was added to the cells without removing the anti-integrin
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side was added at its IC50 for additional 24 h. Caspase 3/7
activity was estimated using the Caspase-Glo 3/7 Assay
(Promega, Madrid, Spain) and quantified on a Polar Star
Galaxy plate reader (BMG, Offenburg, Germany), using
530 emission filters. Three replicates were assayed for
each condition.
To analyze the effects of RGD peptides on the apoptosis
of NSCLC cells, we collected supernatants from A549
and H1299 cultures after cells were transiently trans-
fected with the TGFBI expression vector. The amount of
TGFBI protein in the cell supernatants was estimated by
densitometric analysis of Western-blot bands using as
reference, the intensity of 10 ng of recombinant protein
loaded in the first lane of each gel. NSCLC cell superna-
tants were collected 24 h later and filtered through a 3
kDa exclusion column (Centricon, MA, USA). Both the
concentrate (TGFBI < 3 kDa) and the filtrate (TGFBI > 3
kDa) were added to different A549 and H1299 cultures at
a final concentration of 1× for 4, 8, 12 or 24 h. At each
time-point, caspase 3/7 and caspase 8 activity were mea-
sured using the Caspase-Glo Assay (Promega) as above.
Statistical analysis
Non-parametrical Kruskal-Wallis and pairwise Mann-
Whitney U tests were used to compare TGFBI expression
in NSCLC samples according to response to treatment.
To asses overall survival, Kaplan-Meier curves were cal-
culated and comparison was performed by log-rank test.
The median (H-score 150) was chosen as a cut-off point.
Student t-test statistical analysis was performed to com-
pare different treatments in the vitro experiments. All the
analyses were performed using SPSS 15.0 (Chicago, IL). A
p value less than 0.05 was considered statistically signifi-
cant.
Figure legends for additional figures and additional
Material and Methods are provided as additional files 8
and 9 respectively.
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